Conference highlights industry leaders and innovators in the psychedelic therapy space and features Michael Pollan, author of New York Times bestseller, “How to Change Your Mind”
- Will present at Canaccord Genuity’s “New Paradigms & Treatment Approaches in Mental Health” conference on February 3rd and 4th, 2021.
- Two-day virtual conference will explore the science, intellectual property, and legality of psychedelic compounds, which are at the forefront of breakthrough medical science.
- Novamind’s CEO and Director, Yaron Conforti will present on Wednesday February 3rd from 1:30-1:55 PM.
TORONTO, ON / January 29, 2021 / Novamind Inc. (CSE:NM) (“Novamind”), a mental health company specialized in psychedelic medicine, today announced that it will present at Canaccord Genuity’s “New Paradigms & Treatment Approaches in Mental Health” conference on February 3rd and 4th, 2021.
The two-day virtual conference will explore the science, intellectual property, and legality of psychedelic compounds, which are at the forefront of breakthrough medical science. Novamind’s CEO and Director, Yaron Conforti will present on Wednesday February 3rd from 1:30-1:55 PM.
Novamind, which has administered over 5,000 ketamine therapy treatments since 2016 and hosted over 20,000 client visits to its clinics in 2020 alone, will share its vision for scaling access to psychedelic medicine and advancing clinical research.
The conference will also feature keynote speaker Michael Pollan, author of the #1 New York Times bestseller “How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence.”
For more information about the conference, please click here.
Read More: https://agoracom.com/ir/Novamind/forums/discussion/topics/754196-novamind-to-present-at-canaccord-genuity-conference-new-paradigms-treatment-approaches-in-mental-health/messages/2300955#message
Tags: COMPASS PATHWAYS, CSE, Field Trip Health Ltd., MIND MEDICINE (MINDMED) INC, NUMINUS WELLNESS INC, Psyched Wellness Ltd., Psychedelic, psychedelic medicine, Revive Therapeutics, small cap stocks, stocks